Abstract 5015
Background
Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers in china. Because the disease often has no symptoms in the early stages, it is usually detected at a more advanced stage that is more challenging to treat. The inter-communication between esophageal squamous cell carcinoma and its surrounding microenvironment is essential for tumor progression and metastasis. Exosome plays a key role in information delivery between primary lesion and pre-metastatic niche via its packed bioactive molecules. The aim of this study is to explore the effect of exosome from tumor plasma to angiogenesis in human lymphatic endothelial cells (HLEC) in vitro.
Methods
Total circulation exosomes (CEs) were extracted and purified to selectively capture EpCAM positive exosomes by magnetic-bead technique. Proteins were separated by SDS-PAGE, and protein bands were analyzed by mass spectrometry. Tube formation assay and fluorescence imaging assay were performed in vitro.
Results
The expression level of CEs in ESCC patients with lymph node metastasis were significantly higher than that in ESCC patients without metastasis and healthy control group (respectively; P < 0.001). The tumor associated exosomes could be taken by HLEC and its transferred into HLECs could to promote HLECs tube formation in vitro. In addition, the mass spectrometry was used to analysis the proteomic content in tumor associated exosomes, tumor-related proteins such as matrix-metalloproteinases, PP2A proteins and EIF proteins were identified in the exosome.
Conclusions
Exosomes released by ESCC may play important roles in the microenvironment of ESCC and provide a potential application of therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhejiang Cancer Hospital.
Funding
NSFC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4228 - Clinical Evaluation of Drug-Eluting Bead Transcatheter Arterial Chemoembolization(D-TACE) versus Conventional TACE in Treatment of unresectable Hepatocellular Carcinoma
Presenter: Yi Chen
Session: Poster Display session 1
Resources:
Abstract
3930 - Safety profile of tepotinib in patients with advanced solid tumors: pooled analysis of phase I and II data
Presenter: Thomas Decaens
Session: Poster Display session 1
Resources:
Abstract
5373 - Drug-drug interaction profile of tepotinib with CYP3A and P-gp substrates
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
5455 - Bioavailability of tepotinib: impact of omeprazole and food
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
2618 - Tislelizumab Exposure-Response Analyses of Efficacy and Safety in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2563 - Population Pharmacokinetics of Tislelizumab in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2021 - The Addition of Metformin to Systemic Anticancer Therapy
Presenter: Jung Han Kim
Session: Poster Display session 1
Resources:
Abstract
5243 - Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients
Presenter: Antoine Italiano
Session: Poster Display session 1
Resources:
Abstract
598 - Analysis of the overall survival and main surrogates used for FDA approvals in solid and hematological malignancies.
Presenter: Maria Kleniewska-Wieczor
Session: Poster Display session 1
Resources:
Abstract
5381 - Comparison of intratumoral docetaxel exposure in cancer patients between nanoparticle entrapped docetaxel (CPC634) and conventional docetaxel (Cd): the CriTax study
Presenter: Ruben Van Eerden
Session: Poster Display session 1
Resources:
Abstract